These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
768 related articles for article (PubMed ID: 26626800)
1. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800 [TBL] [Abstract][Full Text] [Related]
2. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol. Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671 [TBL] [Abstract][Full Text] [Related]
3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection]. Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920 [No Abstract] [Full Text] [Related]
4. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T; Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ; Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693 [TBL] [Abstract][Full Text] [Related]
6. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. Cho JH; Lim JY; Cho JY PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Honma Y; Yamada Y; Terazawa T; Takashima A; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Ohashi M; Morita S; Fukagawa T; Machida N; Katai H Surg Today; 2016 Sep; 46(9):1076-82. PubMed ID: 26563224 [TBL] [Abstract][Full Text] [Related]
9. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012 [TBL] [Abstract][Full Text] [Related]
10. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy. Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H; Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689 [TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678 [TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. Feng D; Leong M; Li T; Chen L; Li T World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099 [TBL] [Abstract][Full Text] [Related]
14. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH; Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517 [TBL] [Abstract][Full Text] [Related]
16. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J; Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374 [TBL] [Abstract][Full Text] [Related]
17. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. Wang G; Zhao J; Song Y; Zhang W; Sun Y; Zhou A; Huang J; Du F; Yang L BMC Cancer; 2018 May; 18(1):547. PubMed ID: 29743043 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]